<DOC>
	<DOCNO>NCT01462149</DOCNO>
	<brief_summary>Neoadjuvant chemotherapy alternative treatment option upfront cytoreductive surgery treat advance ovarian cancer . Paclitaxel plus carboplatin frequently select chemotherapeutic regimen neoadjuvant chemotherapy . Docetaxel similar therapeutic efficacy compare paclitaxel adjuvant chemotherapy trial ovarian cancer . However , docetaxel favorable toxicity profile . Therefore , investigator aim evaluate efficacy docetaxel plus carboplatin neoadjuvant chemotherapy patient advanced ovarian cancer .</brief_summary>
	<brief_title>Efficacy Study Neoadjuvant Chemotherapy Treat Advanced Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Advanced epithelial , tubal , primary peritoneal cancer Cancer cell paracentesis , thoracentesis , laparoscopic surgery Less probability complete cytoreduction Age : 2080 year GOG performance status : 03 Adequate organ function Bone marrow : ANC ≥ 1,500mm3 , Platelet ≥ 100,000/mm3 , Hb ≥ 10.0 g/dl Kidney : Creatinine ≤ 1.25 × UNL Liver : AST , ALT ≤ × 2.5 UNL ( case liver metastasis , AST , ALT ≤ × 5 UNL ) , alkaline phosphatase ≤ 5 x UNL , bilirubin ≤ 1.5 mg/ mm3 Previous chemotherapy pelvic radiation therapy Final diagnosis malignancy Coincidental Other malignancy within 5 year except carcinoma situ uterine cervix History severe allergy Pregnancy , lactate woman Uncontrolled medial disease Bowel obstruction require immediate surgery Etc .</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2011</verification_date>
</DOC>